

This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

## **Patient Group Direction (PGD)**

For the administration or supply of

### **Sodium Cromoglicate 2% Eye Drops**

By registered health care professionals for

### **Management of Allergic conjunctivitis secondary to Hay Fever**

**Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice**

### **PGD NUMBER – 134**

#### **1. Change history**

<b>Version number</b>	<b>Change details</b>	<b>Date</b>
1	Original PGD ratified	June 2021
2	Minor Word changes to improve clarity of document	September 2023

## 2. Medicines practice guideline 2: *Patient group directions*

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care [PGD website FAQs](#).

## 3. PGD development

Refer to the [NICE PGD competency framework for people developing PGDs](#)

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

## 4. PGD authorisation

Refer to the [NICE PGD competency framework for people authorising PGDs](#)

Job Title	Name	Signature	Date
Medical Director			
Deputy to Chief Pharmacist/ Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)	N/A	N/A	N/A

## 5. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the [NICE PGD competency framework for health professionals using PGDs](#)

	<b>Requirements of registered Healthcare professionals working under the PGD</b>
<b>Qualifications and professional registration</b>	<ul style="list-style-type: none"> <li>Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy</li> <li>Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises</li> </ul>
<b>Initial training</b>	<ul style="list-style-type: none"> <li>Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria</li> <li>Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD</li> <li>Local training in the use of PGDs</li> </ul>
<b>Competency assessment</b>	Staff will be assessed on their knowledge of drugs and clinical assessment as part the competency framework for registered health professionals using PGDs
<b>Ongoing training and competency</b>	The registered health care professionals should make sure they are aware of any changes to the recommendations for this medication; it is the responsibility of the registered health care professionals to keep up to date with continuing professional development. PGD updates will be held every two years

## 6. Clinical Conditions

<b>Clinical condition or situation to which this PGD applies</b>	Allergic conjunctivitis secondary to hay fever
<b>Inclusion criteria</b>	Adults and children (12 months and over ) presenting with symptoms of allergic conjunctivitis secondary to hay fever
<b>Exclusion criteria</b>	<ul style="list-style-type: none"> <li>Under 12 months</li> <li>Any known hypersensitivity to any component of the medicine</li> </ul>
<b>Cautions (including any relevant action to be taken)</b>	<ul style="list-style-type: none"> <li>Do not use with contact lenses</li> </ul> <p>A detailed list of cautions is available in the SPC, which is available from the electronic Medicines Compendium website: <a href="http://www.medicines.org.uk">www.medicines.org.uk</a> and BNF <a href="https://bnf.nice.org.uk">https://bnf.nice.org.uk</a></p>
<b>Arrangements for referral for medical advice</b>	Patient should be referred to a more experienced clinical practitioner for further assessment
<b>Action to be taken if patient excluded</b>	Patient should be referred to a more experienced clinical practitioner for further assessment

<b>Action to be taken if patient declines treatment</b>	<ul style="list-style-type: none"> <li>• A verbal explanation should be given to the patient on: the need for the medication and any possible effects or potential risks which may occur as a result of refusing treatment</li> <li>• This information must be documented in the patients' health records</li> <li>• Any patient who declines care must have demonstrated capacity to do so</li> <li>• Where appropriate care should be escalated</li> </ul>
---	--

## 7. Details of the medicine

<b>Name, form and strength of medicine</b>	Sodium Cromoglicate 2% eye drops
<b>Legal category</b>	Prescription Only Medicine (POM)
<b>Indicate any <u>off-label use</u> (if relevant)</b>	None
<b>Route/method of administration</b>	Topical application to the eye/s
<b>Dose and frequency</b>	1 drop to each eye four times a day
<b>Quantity to be administered and/or supplied</b>	1 bottle (13.5ml)
<b>Maximum or minimum treatment period</b>	<ul style="list-style-type: none"> <li>• Maximum four times daily</li> <li>• Once opened, any remaining solution should be discarded after 1 month</li> </ul>
<b>Storage</b>	Store at Room temperature
<b>Adverse effects</b>	<ul style="list-style-type: none"> <li>• Burning/stinging sensation</li> <li>• Blurred vision on instillation</li> </ul> <p>A detailed list of adverse reactions is available in the SPC, which is available from the electronic Medicines Compendium website: <a href="http://www.medicines.org.uk">www.medicines.org.uk</a> and BNF <a href="https://bnf.nice.org.uk">https://bnf.nice.org.uk</a></p>
<b>Records to be kept</b>	The administration of any medication given under a PGD must be recorded within the patient's medical records

## 8. Patient information

<b>Verbal/Written information to be given to patient or carer</b>	<ul style="list-style-type: none"> <li>• On instillation an initial burning sensation may be experienced which may last up to 30 seconds</li> <li>• May cause transient blurring of vision on instillation. Warn patients not to drive or operate hazardous machinery until vision is clear</li> <li>• Verbal information must be given to patients and or carers for all medication being administered under a PGD</li> <li>• Where medication is being supplied under a PGD, written patient information leaflet must also be supplied</li> <li>• A patient information leaflet is available on request</li> </ul>
---	--

**Follow-up advice to be given to patient or carer**

If symptoms do not improve or worsen or you become unwell, seek medical advice immediately

## 9. Appendix A

### References

1. British National Formulary (BNF) available online: <https://bnf.nice.org.uk>
2. Nursing and Midwifery "The code" available online: <https://www.nmc.org.uk>
3. Current Health Care Professions Council standards of practice
4. General Pharmaceutical Council standards
5. Electronic medicines compendium available online: <https://www.medicines.org.uk>

## 10. Appendix B

### Health professionals agreed to practice

- Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor
- A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves